
Arrowhead Pharmaceuticals Completes Global License and Collaboration Deal with Sarepta Therapeutics
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has successfully closed its global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ: SRPT), which was initially announced on November 26, 2024. The closing of this highly anticipated transaction was contingent upon the expiration or…